|
Market Closed -
OTC Markets
00:59:42 18/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 6.450 USD | -28.93% |
|
-29.50% | -54.73% |
Company Valuation: Evofem Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 189.8 | 61.25 | 7.884 | 1.281 | 1.122 | 1.204 |
| Change | - | -67.73% | -87.13% | -83.76% | -12.37% | 7.24% |
| Enterprise Value (EV) 1 | 226.8 | 169.2 | 76.24 | 44.65 | 46.96 | 55.62 |
| Change | - | -25.4% | -54.94% | -41.43% | 5.17% | 18.44% |
| P/E | - | - | - | - | -0.08x | 26.6x |
| PBR | - | - | - | -0.02x | -0.02x | -0.02x |
| PEG | - | - | - | - | - | -0x |
| Capitalization / Revenue | 425x | 7.43x | 0.47x | 0.07x | 0.06x | 0.06x |
| EV / Revenue | 509x | 20.5x | 4.53x | 2.45x | 2.43x | 2.76x |
| EV / EBITDA | -2.2x | -1.02x | -0.92x | -2.57x | -6.68x | 28.4x |
| EV / EBIT | -2.19x | -1.01x | -0.91x | -2.5x | -6.12x | 38.7x |
| EV / FCF | -2.48x | -2.42x | -2.01x | -6.24x | -12.4x | -9.51x |
| FCF Yield | -40.3% | -41.4% | -49.8% | -16% | -8.04% | -10.5% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | - | - | - | - | -180 | 0.5351 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.446 | 8.244 | 16.84 | 18.22 | 19.36 | 20.18 |
| EBITDA 1 | -103.2 | -165.8 | -83.11 | -17.37 | -7.027 | 1.957 |
| EBIT 1 | -103.5 | -166.8 | -84.12 | -17.85 | -7.676 | 1.439 |
| Net income 1 | -142.3 | -205.2 | -76.7 | 52.98 | -8.86 | 0.391 |
| Net Debt 1 | 37.05 | 108 | 68.36 | 43.37 | 45.84 | 54.42 |
| Reference price 2 | 6,777,277.840 | 1,055,961.755 | 11,999.400 | 95.995 | 14.849 | 14.249 |
| Nbr of stocks (in thousands) | 0.03 | 0.06 | 0.66 | 13.3 | 75.6 | 84.5 |
| Announcement Date | 04/03/21 | 10/03/22 | 27/04/23 | 27/03/24 | 24/03/25 | 11/03/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 855M | ||
| 41.43x | 14.03x | 29.73x | 0.48% | 1,261B | ||
| 40.79x | 6.85x | 19.26x | 1.91% | 671B | ||
| 37.33x | 8.57x | 17.72x | 2.36% | 518B | ||
| 21.83x | 5.29x | 13.24x | 2.47% | 387B | ||
| 101.76x | 5.82x | 24.8x | 2.37% | 353B | ||
| 23.99x | 5.78x | 14.05x | 2.75% | 300B | ||
| 23.93x | 4.79x | 13.46x | 1.83% | 283B | ||
| 23.64x | 7.27x | 13.36x | 2.2% | 248B | ||
| -40.04x | 7.4x | 46.61x | 1.94% | 211B | ||
| Average | 30.52x | 7.31x | 21.36x | 2.03% | 423B | |
| Weighted average by Cap. | 36.56x | 8.81x | 22.37x | 1.7% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- EVFM Stock
- Valuation Evofem Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
















